TSP830-CMap - carcinogenome project: Toxicogenomic signatures after exposure to BRD-K63993117


TSA8612-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117


TSA8977-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117


TSA9098-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117


TSA9219-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117


TSF8857-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 20.3 µM


1 subfactor(s)
TSF8856-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 40.6 µM


1 subfactor(s)
TSF8858-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 10.15 µM


1 subfactor(s)
TSF8859-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 5.08 µM


1 subfactor(s)
TSF8860-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 2.54 µM


1 subfactor(s)
TSF8861-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 1.27 µM


1 subfactor(s)
TSF10659-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 102.48 µM


1 subfactor(s)
TSF10660-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 34.16 µM


1 subfactor(s)
TSF10661-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 11.39 µM


1 subfactor(s)
TSF11018-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 11.39 µM


1 subfactor(s)
TSF11016-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 102.48 µM


1 subfactor(s)
TSF11017-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 34.16 µM


1 subfactor(s)
TSF11362-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 102.48 µM


1 subfactor(s)
TSF11363-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 34.16 µM


1 subfactor(s)
TSF11364-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 11.39 µM


1 subfactor(s)
TSF11713-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 102.48 µM


1 subfactor(s)
TSF11714-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 34.16 µM


1 subfactor(s)
TSF11715-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 11.39 µM


1 subfactor(s)
TSS8857-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 20.3 µM


TSS8856-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 40.6 µM


TSS8858-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 10.15 µM


TSS8859-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 5.08 µM


TSS8860-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 2.54 µM


TSS8861-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 1.27 µM


TSS10660-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 102.48 µM


TSS10661-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 34.16 µM


TSS10662-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to BRD-K63993117 11.39 µM


TSS11019-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 11.39 µM


TSS11017-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 102.48 µM


TSS11018-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to BRD-K63993117 34.16 µM


TSS11363-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 102.48 µM


TSS11364-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 34.16 µM


TSS11365-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to BRD-K63993117 11.39 µM


TSS11714-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 102.48 µM


TSS11715-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 34.16 µM


TSS11716-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to BRD-K63993117 11.39 µM



TSP830 - CMap - carcinogenome project: Toxicogenomic signatures after exposure to BRD-K63993117 Public


In the chemical selection process, we prioritized chemicals with long-term rodent liver carcinogenicity annotation for inclusion in this experiment. Long-term carcinogenicity annotations were derived from the Carcinogenic Potency Database (CPDB) (Fitzpatrick 2008). Additional chemicals without carcinogenicity annotation were included on the basis of interest to the Superfund Research Program (environmental toxicants), presence in controversial commercial products (included for predictive purposes), and evidence of binding to the aryl hydrocarbon receptor (AhR), as the AhR is an important mediator of xenobiotics, including carcinogens. In total, 330 unique chemicals were used in the analysis, including 128 carcinogens, 168 noncarcinogens, 100 genotoxicants, and 161 nongenotoxicants. (Li et al., 2019)

Experimental design


No experimental design provided

Results


No results provided